Bexion Pharmaceuticals to Participate in Major Oncology Event
Bexion Pharmaceuticals, Inc., a forward-thinking biopharmaceutical company, focuses on crafting innovative biologic therapies aimed at improving the treatment landscape for solid tumor cancers and alleviating chemotherapy-induced peripheral neuropathy (CIPN). Excitingly, the company has announced that two of its pivotal abstracts have been accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.
Highlights of the Accepted Abstracts
The ASCO Annual Meeting, a significant event in the field of oncology, is scheduled for May 30 - June 3. Bexion’s participation underscores its commitment to advancing cancer treatment and enhancing patient care. The accepted abstracts reveal promising research findings that could pave the way for new treatment modalities.
Abstract One: BXQ-350 and Neuronal Environments
This study explores the effects of BXQ-350, a uniquely designed sphingolipid metabolism modulator, on neuronal environments through the modulation of specific gene pathways. This research provides insights into how BXQ-350 may influence the biology of tumor cells and their surrounding environments, potentially leading to enhanced therapeutic outcomes.
Abstract Two: Safety of BXQ-350 in Pediatric Patients
The second abstract discusses a Phase 1 study investigating the safety and tolerability of BXQ-350 in pediatric patients diagnosed with diffuse intrinsic pontine glioma and diffuse midline glioma. Such research is crucial as it addresses the pressing need for effective treatments for these challenging conditions.
About BXQ-350
BXQ-350 stands out as Bexion's lead drug candidate, showcasing a first-in-class biologic mechanism involving the multifunctional sphingolipid activator protein, Saposin C. In early Phase 1 clinical trials, BXQ-350 has demonstrated a commendable safety profile alongside evidence supporting its single-agent efficacy across various solid tumor types. Additionally, preliminary data suggests that BXQ-350 may address chemotherapy-induced peripheral neuropathy, an area of significant unmet medical need.
About Bexion Pharmaceuticals
Bexion Pharmaceuticals is devoted to developing a new generation of therapies targeting solid tumor cancers and CIPN. The company is actively expanding its research portfolio beyond these initial targets and has generated promising data across multiple classes of solid tumors, including colorectal cancer and pediatric brain tumors. Notably, Bexion has also made substantial progress in its ongoing clinical trials, including a Phase 1b/2 study assessing BXQ-350 in combination with established standard care treatments.
Contact Information
Investor Relations
For inquiries regarding investment opportunities, please reach out to William Windham from Solebury Strategic Communications at 646-378-2946.
Media Relations
For media inquiries, Joyce LaViscount from Bexion Pharmaceuticals is available at 859-446-7386.
Frequently Asked Questions
What is BXQ-350?
BXQ-350 is Bexion's leading drug candidate, targeting solid tumor cancers with a unique mechanism involving sphingolipid modulation.
When will the ASCO Annual Meeting take place?
The ASCO Annual Meeting is scheduled for May 30 - June 3.
What are the major aims of the accepted abstracts?
The abstracts focus on the effects of BXQ-350 in cancer treatment and its safety in pediatric patients.
How is Bexion Pharmaceuticals contributing to oncology?
Bexion is developing innovative biologic therapies aimed at improving outcomes for patients with solid tumors and CIPN.
Who can I contact for more information about Bexion?
For investor inquiries, contact William Windham; for media inquiries, reach out to Joyce LaViscount.
